Balancial and Helius Launch New Medical Cannabis Product in Denmark
Balancial has partnered with Helius Therapeutics from New Zealand to introduce new medical cannabis products in Denmark. This collaboration enables the launch of Helius Therapeutics' cannabis extracts in the Danish market. The first product has already been listed on the Danish Medicines Agency's register of approved cannabis products.
The new product, Helius THC25, is an oral solution (oil) containing an extract of Cannabis sativa L., flos (cannabis flower), cultivated and produced in New Zealand.
This partnership combines Helius Therapeutics' advanced expertise in cannabis cultivation and extraction with Balancial’s strong local presence. Together, the two companies aim to meet the growing demand for medical cannabis in Denmark.
Medical Cannabis: A Different Approach to Medicine
Unlike traditional pharmaceuticals, which typically contain a single active ingredient, medical cannabis consists of plant extracts from different cannabis strains. This can result in variations in how products from different suppliers affect individual patients.
Regulations and Market Context
Medical cannabis has been regulated in New Zealand since the launch of the Medicinal Cannabis Scheme in April 2020. Similar to Denmark, this framework ensures that all products meet strict safety and quality standards. Helius Therapeutics introduced its first products to the New Zealand market in 2021.
Denmark’s medical cannabis pilot program, launched in January 2018, grants patients access to products regulated and approved by the Danish Medicines Agency. Currently, approximately 10,000 patients in Denmark are undergoing treatment with medical cannabis, highlighting the increasing demand and acceptance of this treatment option.
"Our partnership with Balancial is a significant milestone in our mission to expand access to GMP-quality medical cannabis. We are pleased that our New Zealand-grown extracts also meet the high standards of the Danish market," says Carmen Doran, CEO of Helius Therapeutics.
"Finding a supplier capable of delivering products that meet Denmark’s strict quality requirements has been a challenging and time-consuming process. We are therefore very pleased with our collaboration with Helius Therapeutics and the fact that we now have our first product ready," says Bo Tandrup, CEO of Balancial.
Commitment to Medical Education
As part of their partnership, the two companies have committed to providing educational support for healthcare professionals. This includes detailed product information and best practices for patient treatment. The goal is to equip healthcare providers with the necessary knowledge and resources to offer qualified guidance and optimize patient care.